Latest / CME Outfitters Medical Education / Breaking Barriers – Implementing Status-Neutral HIV Screening and Prevention for All
Transcript
- 0:01SPEAKER_03: Hello and welcome.
- 0:02SPEAKER_03: On behalf of CME Outfitters, I would like to thank you for joining us for this CMEO snack titled Breaking Barriers, Implementing Status Neutral HIV Screening and Prevention for All.
- 0:15SPEAKER_03: This program has been supported by an independent educational grant from Gilead Sciences Inc.
- 0:22SPEAKER_03: Today's activity may include discussions of products or devices that are not currently labeled for use by the US FDA.
- 0:31SPEAKER_03: I'm Dr.
- 0:32SPEAKER_03: Oni Blackstock, and I'm the founder and executive director of health justice in New York, New York.
- 0:38SPEAKER_03: I'm delighted to be joined by my colleagues who will help provide broad global perspectives as well as regional insights to this program.
- 0:46SPEAKER_03: I'll let them introduce themselves and then moving forward, we'll use first names.
- 0:51SPEAKER_01: Thank you very much.
- 0:52SPEAKER_01: I'm Christina Musini.
- 0:54SPEAKER_01: I'm a professor of infectious diseases at the University of Modena and Reggio Emilia.
- 0:59SPEAKER_01: And I am a member of the IAS Governing Council, and I'm vice chair of the anti-retroviral therapy European guidelines.
- 1:13SPEAKER_00: Hello everyone, I'm Sadil Solomon.
- 1:15SPEAKER_00: I'm a professor of medicine and epidemiology.
- 1:17SPEAKER_00: I'm also the vice chair for research at the Department of Medicine at Johns Hopkins University in Baltimore.
- 1:23SPEAKER_02: Hi everyone, I'm Bohuma Titanji.
- 1:26SPEAKER_02: I am an assistant professor of infectious diseases and an HIV physician, currently based at Emory University in Atlanta, Georgia.
- 1:35SPEAKER_03: Thank you all for your introductions.
- 1:36SPEAKER_03: We have such an esteemed panel.
- 1:39SPEAKER_03: So the learning objective for today's program is to adopt a status neutral approach to HIV screening to effectively promote prevention strategies, including the initiation of PREPO.
- 1:51SPEAKER_03: Routine screening is a critical first step in the HIV prevention and care continuum.
- 1:58SPEAKER_03: And we know that a healthcare practitioner recommendation for screening has a significant impact on a patient's decision to test.
- 2:07SPEAKER_03: With that said, let's briefly level set on an important distinction between HIV screening versus diagnostic testing before we dive in.
- 2:16SPEAKER_03: HIV screening is routine HIV testing that we offer to all patients in a healthcare setting, regardless of why they came in, whether that's for primary care, the emergency department, or an inpatient admission.
- 2:30SPEAKER_03: Diagnostic testing is what we order when something about the clinical picture raises suspicion of HIV specifically.
- 2:39SPEAKER_03: The status neutral framework is built on screening, on offering this universally, because every test result opens a pathway to care.
- 2:47SPEAKER_03: We also know that this framework helps to reduce stigma and normalizes HIV testing.
- 2:55SPEAKER_03: So to start, I'd like each of you to briefly share one key factor in your region that influences how HIV screening is offered, whether that's stigma, cultural norms, health system structure, or patient perceptions.
- 3:10SPEAKER_03: Christina, let's start first with you.
- 3:13SPEAKER_01: Yeah, I have to say that uh in Italy, um, we wrote also guidelines and a document about testing.
- 3:21SPEAKER_01: Uh, we can have we can face two different variants.
- 3:25SPEAKER_01: One is uh uh to people level.
- 3:29SPEAKER_01: You know, the problem is that they don't perceive sometimes that they are at risk, they don't include HIV among the possible uh infection that people could acquire uh during unprotected sex, so they don't go and test for HIV.
- 3:48SPEAKER_01: While the the second one is about doctors, and I think that this uh is uh really the same.
- 3:56SPEAKER_01: I mean, they think in an old way, you know.
- 4:02SPEAKER_01: They think that people who live with HIV have it written on their, you know, uh on their face, but it's not like this.
- 4:12SPEAKER_01: Really, everybody could uh could uh uh have uh uh met HIV during their life.
- 4:20SPEAKER_01: So I think that uh we really have a long way to go in order to overcome these two barriers, either in uh healthcare practitioner or either in people who have to test themselves.
- 4:37SPEAKER_01: Why don't you share with us your perspective?
- 4:40SPEAKER_00: Thanks, Oni.
- 4:41SPEAKER_00: Um I work across the world, but I'm gonna try and focus more on India because it's a different setting altogether.
- 4:46SPEAKER_00: So in India, we actually end up having thousands and thousands of facility-based screening centers, but then they have to go for testing.
- 4:53SPEAKER_00: Uh, and I think this is something that's common across the world where our primary focus has really been on the access side, trying to make these tests available.
- 5:03SPEAKER_00: But I think populations and their perceptions of risk has changed.
- 5:07SPEAKER_00: The way people want services delivered has also changed with self-care and self-testing taking a bigger role.
- 5:12SPEAKER_00: So I think one of the biggest barriers for me, the way I see it in India and many other settings, is generating that demand among the populations that are vulnerable to HIV to actually seek out HIV testing.
- 5:25SPEAKER_02: Yeah, I currently practice in the US, and one of the biggest barriers that we see, particularly here, is still a lot of uh perception of risk is quite different.
- 5:37SPEAKER_02: And again, there are so many people who don't feel that they are at risk for HIV because a lot of the population still particularly feels that it's it's isolated to certain communities like MSM or people who are coming from overseas, and you might find that it's just not intuitive for people who are not in these demographics to seek out testing or even understand why you might be recommending that they get tested for HIV and know their status.
- 6:08SPEAKER_02: On the side of the providers who actually offer HIV testing, you also see another barrier in the context, particularly in the hospital, where there's always the question of who is then going to discuss the result with the patient.
- 6:24SPEAKER_02: And people sort of turf this to the outpatient setting with your primary care provider as being the person that should be offering you HIV testing.
- 6:33SPEAKER_02: And so there are missed opportunities, particularly for people who may not have health insurance and maybe getting their care primarily through the emergency rooms, if there's not that proactive approach to offering testing.
- 6:46SPEAKER_03: Yeah, so that's really helpful.
- 6:48SPEAKER_03: So we heard some individual-level similarities in terms of low perceived risk, providers maybe not thinking that patients are at risk and therefore not offering testing, providers not wanting to have to deal with what happens, you know, if someone tests positive and having to have that conversation, and then also sort of access and building demand for screening.
- 7:08SPEAKER_03: So, Sunil, you work across multiple global contexts.
- 7:11SPEAKER_03: And I'm wondering if you could walk us through where the guidelines align and where you see the biggest disconnect between what's actually recommended and then what's happening on the ground.
- 7:25SPEAKER_00: Yeah, so I think we have several guidelines.
- 7:27SPEAKER_00: Like, for example, we have the CDC guidelines, we have the WHO guidelines, we have the European testing guidelines, and then several countries have their own national guidelines, but most of them sort of align with the WHO guidelines themselves.
- 7:39SPEAKER_00: And I think the one similarity across all these guidelines is they all normalize HIV testing.
- 7:44SPEAKER_00: They all suggest that we should be screening everyone for HIV, it should be routine, and there's also a very strong emphasis on linkage beyond the testing.
- 7:55SPEAKER_00: So once you screen, if they screen positive, then the linkage to diagnostic testing, and then whether it's like PrEP or whether it's ART, that that pathway needs to be continued.
- 8:05SPEAKER_00: And I think these are sort of recommendations across all the guidelines.
- 8:11SPEAKER_00: Uh, the biggest disconnect I would say is these guidelines generally tend to be focused on the general population, versus like when you start going outside of sub-Saharan Africa, the majority of infections seem to be happening in either key populations or their partners.
- 8:30SPEAKER_00: And these are populations that face several challenges accessing HIV testing, whether it's stigma, whether it's logistics, or whether it's just distance, right?
- 8:41SPEAKER_00: And I think that's something that hasn't really been addressed on how do you access or how do you improve access to HIV testing to populations that are not able to come to the traditional testing venues like the testing center, like the integrated counseling and testing centers or the laboratories that are established, whether it's part of PEPFAR or part of government programs or CDC.
- 9:05SPEAKER_00: And this is extraordinarily clear when you start looking at the HIV care continuum and the HIV care cascade.
- 9:14SPEAKER_00: When you start splitting it, even in countries that have great cascades, when you split the cascade by population at risk, you tend to see large drop-offs the minute you go to populations like trans people or cisgender men who have sex and men, especially in sub-Saharan Africa, where it's criminalized in many settings.
- 9:31SPEAKER_00: Or if you go to India, people who inject drugs, they're significantly lower.
- 9:35SPEAKER_00: And I think that's where the guidelines need to modify or give us examples of what strategies work in these populations.
- 9:46SPEAKER_00: But other than that, I would say like most of the guidelines are in alignment with each other, really recommending and normalizing HIV testing.
- 9:55SPEAKER_03: Okay, that's really great.
- 9:56SPEAKER_03: So it sounds like, again, you said they are all promoting routine testing, normalizing it, but it sounds like in terms of reach, reaching those communities or those groups that are most vulnerable and giving examples of how to do that.
- 10:08SPEAKER_03: Um, Christina, I'm wondering, so the status neutral framework in many ways changes the question from what is your status to what do you need?
- 10:17SPEAKER_03: And I'm wondering if you could walk us through how this works in practice.
- 10:22SPEAKER_01: Yeah, I really think that uh is the way to put in practice um all the uh, you know, the development, all the uh different approaches uh that we have found along these 30 years or 40 years of the epidemic.
- 10:43SPEAKER_01: I mean, I think that we have had so many uh progress uh in treatment and more recently so many achievements in PrEP, that this kind of model really put the person at the center and provide the person who tests with the true option.
- 11:09SPEAKER_01: That is, if your test is positive, so you will have the best treatment.
- 11:16SPEAKER_01: If your test is negative, uh you can have access to the prevention that could be prevention in with the with the drug, but also the counseling, you know, with uh safe sex, whatever, is just something.
- 11:34SPEAKER_01: Uh it's a model that uh provides people who test with not just a test, but just the beginning of a pathway, either of treatment or of prevention.
- 11:49SPEAKER_01: And I think that this is something that is uh in a way new, because we are used to say, you know, the the person look at the result of the test and that's it.
- 12:02SPEAKER_01: But with this incredible achievement that we had in treatment and in prevention, uh it would be terrible not to share it.
- 12:14SPEAKER_01: I'll give you an example.
- 12:17SPEAKER_01: In my hospital, um people who came to infectious diseases were receiving this kind of approach.
- 12:25SPEAKER_01: While people who went to sexually transmitted disease uh clinic, they just tested and they received the treatment for sexually transmitted diseases, but they were not counseled about PrEP.
- 12:40SPEAKER_01: So we changed it, we just uh train the dermatologist and uh on PrEP, and in this way we could reach the status-neutral uh HIV prevention and care model.
- 12:55SPEAKER_01: I think, and I think that this is very important.
- 12:59SPEAKER_03: Thank you, Christine.
- 13:00SPEAKER_03: I love the example of the dermatologists integrating the screening into their practice.
- 13:04SPEAKER_03: Um, I'm wondering if Bohuma or Sunil have um any reflections around whether this framework resonates with how testing is done in the settings that you work in.
- 13:15SPEAKER_02: I think that the framework in the setting that I work in, there's still a lot of room for improvement because there are lots of providers who don't yet have the reflex of nope thinking ahead, I'm offering testing, what would I do with the test result when the test is here?
- 13:34SPEAKER_02: There's still a great perception that anything related to HIV should be relegated to sexual health doctors and infectious diseases doctors, which means that even when you have an individual who has an HIV negative test who ought to be offered a PrEP, that reflex is not immediately there.
- 13:55SPEAKER_02: The what we are still seeing a lot in practice is, okay, your HIV test is negative and that's it, right?
- 14:01SPEAKER_02: So currently at our um large county hospital where we work, we are currently uh piloting uh uh a sort of like the status neutral approach where every HIV negative uh test automatically reflexes to engaging with uh offering that individual prep and providing them with the resources if they want to go to the prep clinic and learn more, or for those who want a prescription before they leave the hospital, being able to get that prescription before they get discharged.
- 14:38SPEAKER_02: And what that does is again, it emphasizes that linkage to care piece, right?
- 14:43SPEAKER_02: You're not deferring it to some time down the line where there's more of a risk for loss, so that person being lost to follow up.
- 14:51SPEAKER_02: So it's going to be very exciting to see if that is the thing that our providers need to kind of fill that gap where they're thinking more proactively about negative test, I offer prep, positive test, I link the patient to care and start treatment.
- 15:09SPEAKER_00: The only thing I would probably add to the discussion is like I think in terms of status neutral HIV prevention and care, I would also go one step further back and say status neutral person-centered HIV prevention and care.
- 15:22SPEAKER_00: Because I think for many people infected and affected by HIV, HIV testing is not their priority.
- 15:28SPEAKER_00: And I think we've seen this in many settings in the US and globally where access to services like gender affirming care or access to services like laser hair removal or food and shovers are what draw populations who are really vulnerable into these facilities.
- 15:44SPEAKER_00: And once they're in, the platform of status neutral HIV care can begin, right?
- 15:49SPEAKER_00: So you get them their access to gender affirming care, and when they're there, say, hey, can we also screen you for HIV?
- 15:54SPEAKER_00: And if they're positive, then you go down the positive pathway, or the negative, you go down the negative pathway.
- 15:58SPEAKER_00: But I think we also had to start thinking about what people want versus what we think people want.
- 16:05SPEAKER_03: Totally, yes.
- 16:06SPEAKER_03: I think bundling the screening with things that people care about, services that people actually want, um, definitely helps to increase um uptake.
- 16:14SPEAKER_03: Um, so I'm wondering if you can tell me um about or walk us through, you kind of mentioned a little bit earlier about these kind of these two pathways and the benefits of acting on both.
- 16:26SPEAKER_03: So whether someone has a reactive screening test or a negative test.
- 16:30SPEAKER_02: Yeah, I I would uh I think I I can draw from my practice quite readily, in the sense because I'm teaching about this all the time, uh, that whole pathway, as we've talked about before, is like in the context of someone having an HIV negative test, the next uh conversation that I'm engaging that person with is kind of understanding what a negative test means, and also the fact that a negative test at that time point is not a static thing.
- 17:00SPEAKER_02: Based on your exposures and kind of your sexual health behaviors, you may be exposed to HIV down the line, and that status could change.
- 17:10SPEAKER_02: And there are ways that you can ensure that your test remains negative by, you know, considering PrEP.
- 17:16SPEAKER_02: And then I have the conversation about offering them PrEP, talking about what PrEP is and what the options we have for PrEP are, and then you know, directing them towards one direction of where they can actually access these services.
- 17:31SPEAKER_02: Now, in the back of my mind, also we we always know that we it's not everyone who would show up with a negative test.
- 17:39SPEAKER_02: For those individuals that have a positive test, we are also accelerating linkage to care.
- 17:45SPEAKER_02: So again, providing counseling immediately about what it means to live with HIV currently, emphasizing on the fact that putting people on treatment as soon as possible after diagnosis leads to better outcomes, and you can go on to have a very normal, healthy life if you are treated, and then providing those resources to connect them to care so that they can uh start treatment promptly and stay engaged in their care.
- 18:12SPEAKER_02: And I also use that um discussion about the test result to also have uh a discussion around just sexual health in general.
- 18:23SPEAKER_02: And you know, that still involves kind of having conversations about other aspects of harm reduction, talking about uh condom use and looking for other um behaviors that may be adding or kind of a component of an individual's particular risk profile.
- 18:44SPEAKER_02: So is that person using in in injection drugs and are there opportunities to connect them to a needle exchange program and other things that would optimize their health and make sure that they are staying negative if they test it negative, or if they're HIV positive, making sure they're connected to care and have the right resources to take care of their health.
- 19:06SPEAKER_03: Yeah, that's wonderful.
- 19:07SPEAKER_03: And I think so much of what you talked about was around also education and identifying resources for folks, regardless if they have a reactive test or a test negative.
- 19:15SPEAKER_03: Um, and the education part, I think, addresses some of the sort of misinformation and misconceptions that people can have that can often be barriers to effective HIV screening.
- 19:25SPEAKER_03: So, from your experiences, um, what misconceptions among patients or clinicians most often interfere with a status neutral approach in your region?
- 19:36SPEAKER_03: And you can pick one misconception and share that with us, and we'll start, Christina, um, with you.
- 19:42SPEAKER_01: Yeah, as I said before, I think that uh the most important, the most relevant is the one that you could uh see uh HIV from the face of someone.
- 19:57SPEAKER_01: I can tell you that I was uh like uh an expert in a trial of a lady who died of HIV, unfortunately.
- 20:08SPEAKER_01: And uh she was a lawyer, so nobody tested her because she was a lawyer.
- 20:15SPEAKER_01: So, you know, that's the problem.
- 20:18SPEAKER_01: And uh it was something that explains, I think, more than a thousand words.
- 20:24SPEAKER_01: Yeah, after all these years, there is still this misconception.
- 20:29SPEAKER_01: So either in the people say, you know, maybe I'm a lawyer, I don't test, because I think that my husband is faithful.
- 20:38SPEAKER_01: So the information is uh something that is uh absolutely crucial to improve, because the other possibility is to test really everybody and to normalize the testing like cholesterol.
- 20:56SPEAKER_01: You know, you test for cholesterol, you test for HIV, and this would be the most important thing.
- 21:03SPEAKER_01: But uh until then, um we really have to fight about this misconception and the risk perception, I think.
- 21:16SPEAKER_00: And I can go next, and I think uh from a patient side, fear of judgment, fear of being thought of as a bad person or someone who engaged in a bad behavior is one of the biggest barriers.
- 21:25SPEAKER_00: And from a provider perspective, I would say the biggest barrier is like we think people want an HIV test, but most people don't.
- 21:32SPEAKER_00: Yeah.
- 21:33SPEAKER_02: Yeah.
- 21:34SPEAKER_02: And I would I would round it out by saying stigma is still pretty huge.
- 21:38SPEAKER_02: Uh, I've encountered so many patients uh for whom you you know you might offer screening, and they would say, I've not been screened, but I would rather not know.
- 21:48SPEAKER_02: And when you try to probe a little bit, you find out that the reason why they are not interested in getting an HIV test is because they don't want to have the conversation that comes after the test.
- 22:00SPEAKER_02: Where the stigma is so strong that you know even the possibility of having a negative test is still not something they want to engage with.
- 22:09SPEAKER_02: And that in itself tells uh leads the patient to reject the test when it's offered.
- 22:15SPEAKER_01: Yeah, I would say that we we have a long way to go, for example, with you equal you.
- 22:21SPEAKER_01: Because this idea, you know, this fear of being test tested, it's something that dates back in the early time of the early year of the epidemics when uh it was like HIV equal death.
- 22:35SPEAKER_01: And still today that we have uh, well, I mean, uh active drugs, so tolerated drugs, and uh that if you have fear of being tested uh, even if uh I mean maybe you don't realize that it's not a death sentence anymore from since uh a long time ago.
- 22:56SPEAKER_01: I mean, so it's just uh uh many messages that are very clear for the uh healthcare providers, uh, at least infectious disease specialists, I would say, they are not uh being so uh, you know, um received by the by the the so-called general population, whatever it means.
- 23:23SPEAKER_03: Christina, and you mentioned you equals you.
- 23:25SPEAKER_03: Can you just spell that out like with the whole entire phrases and what it refers to just where our audience?
- 23:32SPEAKER_01: Yeah, it's uh undetectable equal untransmittable.
- 23:35SPEAKER_01: It means that if your viral load, plasma viral load is undetectable, you cannot transmit uh HIV.
- 23:43SPEAKER_01: And this is something that is really revolutionary for me.
- 23:47SPEAKER_01: And it's the first thing that I say when I cancel someone uh uh who tested positive because I think that uh uh the stigma and especially the self-stigma, you know, uh it's something that we have to fight.
- 24:06SPEAKER_03: Thank you, Christina.
- 24:07SPEAKER_03: Yes, and you all shared you shared that stigma plays a role, assumptions about one's own risk or the assumptions that we make as clinicians, the assumptions that we make around whether screening is a priority for our patients, um, discomfort that we might have as practitioners having these conversations, these all um weigh in, all of those play a role.
- 24:31SPEAKER_03: Um, and and you may have answered some of this already.
- 24:35SPEAKER_03: Um we know that sometimes these barriers can show up differently depending on local context.
- 24:40SPEAKER_03: And so I wonder if each of you could briefly highlight one specific regional barrier that most strongly affects testing in your a specific setting.
- 24:52SPEAKER_00: I can go first in terms of like I'm gonna focus on India and Asia because it's different from the US, which I think I'll talk about.
- 25:00SPEAKER_00: But I think in terms of um, so the populations, like I said, have shifted, right?
- 25:04SPEAKER_00: The way they're seeking out partners and everything has changed.
- 25:06SPEAKER_00: There's a lot of virtual networking, especially looking for partners through platforms like Grinder and Tinder and Blued.
- 25:13SPEAKER_00: So this is a population that's not showing up in physical venues to take HIV testing.
- 25:20SPEAKER_00: So we've actually transformed our programs in India to go online.
- 25:25SPEAKER_00: So we're actually offering HIV services completely online where we have counselors that talk to people.
- 25:30SPEAKER_00: So I think this goes back to the point of like meeting people where they're at.
- 25:34SPEAKER_00: And and if people, we need to make sure our programs are adaptable and flexible and nimble to change as people's requirements and people's needs are also changing.
- 25:48SPEAKER_00: So in India, we're actually looking at like all these other approaches.
- 25:50SPEAKER_00: Like, can we go into virtual platforms?
- 25:53SPEAKER_00: Can we integrate HIV testing into places where people come to find food?
- 25:57SPEAKER_00: Can we integrate, which are not traditional venues where we're we're offering HIV testing?
- 26:01SPEAKER_00: So I think if we want to get to that last group of people who haven't been reached, we need to stop with our routine and start thinking outside the box on what could work in these populations.
- 26:12SPEAKER_02: Yeah, and I would say kind of uh just to add for the US, the other thing that is a specific challenge is how people perceive HIV currently in the US.
- 26:22SPEAKER_02: It's a in the general population, in the manner of speaking, there's a perception that HIV is over and done with.
- 26:29SPEAKER_02: It's no longer a problem.
- 26:31SPEAKER_02: And what that leads to is that, you know, getting tested for HIV is not at the fore, or it's not something that people are necessarily thinking about as a component of their care.
- 26:44SPEAKER_02: And we also see that not only in the patient populations that engage with the healthcare system, even in the healthcare providers.
- 26:52SPEAKER_02: For healthcare providers who may not be working in the southeastern US where the epidemic is currently concentrated, people are not necessarily thinking that I should be offering HIV testing routinely to every adult at least once a year as part of their health care.
- 27:11SPEAKER_02: And I think that we have to change those perceptions to really encourage people, uh providers to actively offer testing and to remind the population that, for example, in the case of the US, 13% of people with HIV do not know their HIV status.
- 27:29SPEAKER_02: And the only way we're able to reach that 13% and get make sure that they are tested and connected to care is by being proactive in getting people to recognize there's a need to know your status as an individual, and on the provider side, really reminding providers that HIV testing is an integral part of uh the care that we provide to people we we have the privilege of looking after.
- 27:56SPEAKER_03: So let's shift from barriers to implementation.
- 28:00SPEAKER_03: Um, can each of you share one practical example of a challenge you've encountered and how a regional approach has helped to operationalize the status neutral approach?
- 28:11SPEAKER_01: I think that uh our problem is that uh uh you know uh the the possibility to uh to provide the test uh with opt-out is not on the table.
- 28:24SPEAKER_01: See we are changing the we are changing the law that the the law on HIV dates back in 1990.
- 28:34SPEAKER_01: And uh, you know, with all the stigma, it carries all the stigma that was there when people were dying.
- 28:41SPEAKER_01: So now the situation is completely different.
- 28:43SPEAKER_01: We wanted to have the opt-out, but uh it was very, very complicated.
- 28:49SPEAKER_01: Uh so we we have maintained uh obviously the consensus, uh, trying imagine it in the law now.
- 28:57SPEAKER_01: It is written that they have to sign to do the test.
- 29:01SPEAKER_01: Imagine the barrier to sign for the test.
- 29:05SPEAKER_01: We don't do it, uh, but we are against the law, I have to say.
- 29:08SPEAKER_01: So we have to inform uh people, but we cannot prescribe the testing, you know, HIV testing uh like this.
- 29:17SPEAKER_01: Uh you have to explain that you are doing the test, and uh so and this creates stigma, I think, because it should be absolutely in the um uh in the um status neutral approach, it should be very natural, you know.
- 29:35SPEAKER_01: While if you put a lot of uh pressure on it with the counseling, with everything, it's more difficult.
- 29:42SPEAKER_01: It's more difficult.
- 29:45SPEAKER_00: I think to use an example from India, in 2020, 21, we were trying to establish these status neutral HIV centers for the trans community.
- 29:54SPEAKER_00: So we ended up doing a bunch of focus groups with them and we said which of these services, and we provided like prep, ART, HIV testing, STI screening, which would really be a draw.
- 30:04SPEAKER_00: And they essentially said, if you can do laser hair removal, then you will get the community to come in.
- 30:10SPEAKER_00: So we actually built the model around laser hair removal, and what we found was we were able to get a lot of people who were coming in who were not engaged in existing.
- 30:18SPEAKER_00: Almost 70% of the almost 6,000 trans people use these services in a two-year period, and 70% of them had never been to one of the HIV programs before.
- 30:28SPEAKER_00: But they all came in for the gender affirming care, and while they were there, we offered them HIV screening.
- 30:33SPEAKER_00: Anyone who was positive was linked to antiretroviral therapy, and anyone who was negative was linked on on prep if they were eligible and wanted to be on prep.
- 30:42SPEAKER_00: So I think it's it's we need to start taking community perspectives into the way we design programs, and that's like probably the a lesson from India, but probably a lesson for the world.
- 30:52SPEAKER_02: Yeah.
- 30:52SPEAKER_02: I would say that uh in the US, I'll take again the example of our site.
- 30:58SPEAKER_02: Um we have done several things over the years and continue to build on these to remove the barriers.
- 31:04SPEAKER_02: The first thing I mentioned was the opt-in testing that automatically is is offered to everybody who comes in contact with our healthcare system.
- 31:13SPEAKER_02: And it serves both as a reminder to the healthcare providers to offer the test and also provides the patient with an opportunity to be counseled about the importance of testing and to get tested and know their status.
- 31:25SPEAKER_02: We have had we in terms of people who test positive, we have a rapid start and rapid engagement to care program.
- 31:34SPEAKER_02: So we have uh patient coordinators that immediately and counselors that immediately engage with anyone who has a new test, and they are offered resources on counseling immediately to understand what it means to test positive.
- 31:50SPEAKER_02: Reflexively, they get a consult from an HIV physician, and there is a rapid start for most of these individuals in the hospital at the time of diagnosis, unless they have, say, for instance, a contraindication to starting uh ART rapidly.
- 32:05SPEAKER_02: And now we are piloting the connection to care for PrEP.
- 32:09SPEAKER_02: So that's the other exciting and final component of us removing the barrier to being able to engage people in PrEP in the hospital.
- 32:20SPEAKER_02: And I'll take an example of a recent uh individual that we saw who was offered HIV screening in the course of his uh hospitalization was HIV negative, but had tested positive for other STIs.
- 32:32SPEAKER_02: And then when we engaged with him, we offered him PrEP, and he initially refused.
- 32:38SPEAKER_02: And when we probed, his reason was I don't want a PrEP bottle in my house because it's HIV medication, and someone's going to ask me about it, and I don't want to be having that conversation with my roommates.
- 32:49SPEAKER_02: But when we said, actually, there's injectable prep that we could connect you to, he left with an appointment to get his first shot.
- 32:57SPEAKER_02: And that was the first time he was hearing about PrEP.
- 33:00SPEAKER_02: So again, that pilot is already yielding fruit with us being able to connect people who would not otherwise consider PrEP as an option for them because they have questions around stigma.
- 33:13SPEAKER_02: They may not want oral PrEP for reasons that just their understanding that they may not, they don't know what options are open to them.
- 33:21SPEAKER_02: Being able to engage them in this manner has really taken away a significant barrier.
- 33:32SPEAKER_03: So moving on, we know that all the different approaches that you've shared also depend on how clinicians or staff open the conversation around HIV screening.
- 33:42SPEAKER_03: Um, so Bahuma, I'm gonna ask you what language or strategies have you found help to normalize um testing and prevention discussions?
- 33:50SPEAKER_02: Yeah, I I like uh leading uh my conversations with individuals really from a point of being completely non-judgmental.
- 34:00SPEAKER_02: So I I start usually by telling people, okay, so yay, you your HIV test has result has come back negative, and then um just kind of having a conversation about their understanding of what an HIV negative test is, and what is their understanding of HIV prevention in general.
- 34:22SPEAKER_02: I think that starting out with open questions really allows me to get an understanding of where the person is at in terms of their knowledge around HIV prevention and what options are available to them.
- 34:37SPEAKER_02: And that immediately also allows me to have the conversation of risk perception because I think that one of the biggest barriers is that a lot of people think when you start talking about PrEP, or if you jump straight into PrEP, they're like, oh, PrEP is not for me.
- 34:52SPEAKER_02: I'm not uh a person who has a man who has sex with with other men.
- 34:58SPEAKER_02: I'm a black woman.
- 35:00SPEAKER_02: I that's not something that I should be considering.
- 35:02SPEAKER_02: So approaching it from a uh uh a very neutral and non-judgmental way allows you to have a conversation with people that meets them where they are, and you're able to provide a lot more information and counseling that removes some of those misconceptions.
- 35:20SPEAKER_02: And then I move on to kind of also asking them, you know, saying telling them that my role is to basically make them understand what is available to them, and I go over the options and then ask them what speaks to them and what is most likely to fit into their lifestyle and what they think they would need more information about.
- 35:41SPEAKER_02: And I think that approaching it in this way really helps folks to arrive to a point where they're making the decision that's best aligned with what their goals are.
- 35:52SPEAKER_02: And it it really allows a lot of patients to feel that you're not judging them and that you're on their side in optimizing their health.
- 36:01SPEAKER_03: Definitely.
- 36:01SPEAKER_03: And I'm wondering from your experience um doing work in Cameroon and West Africa, if there's anything that you um can share around, for instance, engaging men in HIV testing.
- 36:14SPEAKER_02: Yeah, I I I think that in those settings in particular, it can be quite different in terms of the approach to how you engage men, or particularly in in terms of their HIV care.
- 36:29SPEAKER_02: There's a lot of taboo around talking about sex in general, and people already approach it kind of like from a place of weariness when you start asking them questions about okay, uh, what type of sex you're having and what kind of exposures you may be you may be having.
- 36:48SPEAKER_02: It it you have to be very culturally sensitive in these settings, and again, emphasizing the fact that this is about finding something that aligns with the individual.
- 37:01SPEAKER_02: It's not about me as a healthcare provider telling that individual what to do.
- 37:07SPEAKER_02: It's about them being able to know what options are available to them to best preserve their health.
- 37:14SPEAKER_02: And I think that when you approach it in that manner, it people are a lot more receptive.
- 37:19SPEAKER_02: Now, kind of talking outside of the group of men, I would highlight that women as well in that particular setting can be challenging to engage where PrEP is concerned, because there's the whole notion that if you're a woman and you're using PrEP, that automatically means that you're promiscuous.
- 37:37SPEAKER_02: You're using it because you're having so much sex that you need to prevent HIV.
- 37:41SPEAKER_02: So again, turning the conversation from to be from the angle of what are you doing for your health that best aligns with your objectives of staying healthy and putting it in a non-judgmental way enables you to engage people better, uh, regardless of their gender in these particular settings.
- 38:03SPEAKER_03: Yes, I agree.
- 38:04SPEAKER_03: I always like the saying it's not about you know what's the matter with the person, which pathologizes them, but what matters to them, like what are their priorities and needs.
- 38:13SPEAKER_00: I have nothing to add.
- 38:14SPEAKER_00: I think Baguma summed it up beautifully.
- 38:17SPEAKER_03: Yes, yes, agreed.
- 38:19SPEAKER_03: Okay, so moving on to this sort of general approach to universal screening, again, regardless of the results, um how we communicate it matters.
- 38:29SPEAKER_03: Um, we want to make sure we deliver the test results um in person if possible, understanding that negative results can be delivered virtually or via phone, um, ensuring that the results are delivered in a confidential manner, um that we deliver the results uh using as best possible an empathic yet direct and tone of voice with our patients or our clients.
- 38:54SPEAKER_03: Um, and then of course, this non-judgmental approach and again showing empathy when addressing our patients' responses to their testing results and being flexible with uh patients' reactions and the needs they may have in the moment, what may need to be explained to them, um, and their ability to make decisions in that moment may vary.
- 39:18SPEAKER_03: Also, a key takeaway here is that clinicians don't need to do everything themselves.
- 39:23SPEAKER_03: If you're not ready to prescribe today, whether it's prepar treatment, knowing who and where to refer patients to is a really important step to make.
- 39:35SPEAKER_03: In the US, guidelines support initiating antiretroviral treatment while confirmatory testing is pending.
- 39:42SPEAKER_03: So the question for us as healthcare practitioners is not whether to act, but how to communicate clearly with the patient about why we're starting treatment now and what the confirmatory process looks like, how long it may take.
- 39:55SPEAKER_03: And we realize that this may differ in different settings, but recognizing that in certain countries and settings, same-day treatment and same-day prep are also the goal.
- 40:05SPEAKER_03: Before we close, we'll briefly touch on key considerations for prep initiation following a negative test and appropriate follow-up.
- 40:12SPEAKER_03: So, Sunil, starting with you, walk us through the pre-initiation steps.
- 40:17SPEAKER_00: Sure.
- 40:18SPEAKER_00: I think to just make clear to everyone, prep is only for people who are HIV negative.
- 40:23SPEAKER_00: So I think probably the most important thing you want to do is confirm the HIV negative status with four-generation antibody antigen test.
- 40:31SPEAKER_00: For people who have recently been exposed to a behavior or a practice which may have placed them at risk for HIV, you could consider doing a nucleic acid test, either an RNA-PCR, one of the, if you're outside of the US, you have point-of-care machines that you can use this.
- 40:46SPEAKER_00: This will help to identify people in the window period and prevent persistence.
- 40:51SPEAKER_00: But I think the two other things that are not HIV related, I would also suggest, especially in many countries where TDF and TAF are still used, is definitely do a hepatitis B surface antigen test and also get a renal function test done because both these medications can will actually impact hepatitis B treatment outcomes as well.
- 41:13SPEAKER_00: And so you want to be very careful if the person you are starting on PrEP is also co-infected with hepatitis B.
- 41:21SPEAKER_03: Great.
- 41:21SPEAKER_03: Thank you, Sunil.
- 41:23SPEAKER_03: Do you have anything to add in terms of linkage?
- 41:26SPEAKER_02: Yeah, I would say once you've ascertained all the things that Sunil has so very clearly laid out, it's important to have the conversation about what the options are for the individual who is considering PrEP for themselves.
- 41:41SPEAKER_02: And once you make the options known to them, also kind of encourage them to think about what best fits their lifestyle and what best fits what they're able to take as PrEP.
- 41:53SPEAKER_02: And then the next thing would be having a conversation about how you direct them to get access to what they've decided on.
- 42:01SPEAKER_02: And I think one key piece of information that I think a lot of providers miss when they're having conversations about PrEP is reminding people who are considering PrEP for their own health that it is completely normal to cycle on and off PrEP because your risk profile or your exposure profile doesn't stay static.
- 42:21SPEAKER_02: And I think that there's still the perception amongst a lot of patients that, oh, is PrEP like a medication now that I have to take every day for the rest of my life?
- 42:30SPEAKER_02: No, you have a conversation of if at some point your exposure profile has changed, if you are going through a period of abstinence or if you're going through a period where you feel that you may not need PrEP, it is totally okay to come off of it.
- 42:43SPEAKER_02: And if that changes, it is again totally okay to be able to go back on PrEP.
- 42:49SPEAKER_02: I think that that usually is something that patients don't realize, and it really helps a lot of people over the hub in being feeling very comfortable about making that decision for their health.
- 43:02SPEAKER_03: Great.
- 43:03SPEAKER_03: Thank you both for highlighting those important steps after negative test result.
- 43:09SPEAKER_03: And so detailed prep prescribing will be covered more deeply in later activities in this series.
- 43:14SPEAKER_03: So stay tuned.
- 43:17SPEAKER_03: So this visual highlights different staff who may be involved in prep delivery.
- 43:23SPEAKER_03: And we understand that team structures may vary based on region and healthcare setting.
- 43:29SPEAKER_03: And so I'd like you all to name the top three, or maybe each person can name one, but um top three essential roles in prep delivery in your region in terms of team members.
- 43:41SPEAKER_03: Roles may be clinical, community-based, or system level.
- 43:45SPEAKER_03: And try to focus on who is essential versus um full workflows.
- 43:51SPEAKER_03: We'll start with you, Christina.
- 43:53SPEAKER_01: Yeah, I have to say that uh uh the you know reimbursement of PrEP uh Was based on the fact that delivery should be made only by doctors.
- 44:04SPEAKER_01: And this is an infectious disease specialist.
- 44:09SPEAKER_01: So this is just something that uh limit but we were among the last countries that uh obtain reimbursement because we obtained it in uh 2023, so very, very recently.
- 44:24SPEAKER_01: So um the only and we don't have uh uh injectable prep because uh of cost, so as in all uh European countries, so um the our only choice is between uh uh everyday or on demand.
- 44:43SPEAKER_01: That's the only choice.
- 44:45SPEAKER_01: But what we do, we collaborate uh um with the pharmacist, and we have some checkpoints when where the PrEP is delivered by peers.
- 44:57SPEAKER_01: So I think that this is the and the most important for now by law is the infectious disease specialist.
- 45:05SPEAKER_01: We are trying to enlarge this uh, you know, the possibility to prescribe PrEP with IFA, but it takes some time, I think, because it was just reinforced.
- 45:16SPEAKER_01: Uh they are not ready to change everything now.
- 45:22SPEAKER_00: If I needed to pick, I would say for oral prep, it would either be counselors or social workers, one of that, those two positions, and someone who could prescribe, depending on which setting you're in.
- 45:32SPEAKER_00: Just those two positions, you should be able to design an effective oral prep program.
- 45:36SPEAKER_00: And for injectable, I would use those same two positions and include someone who could also deliver the injectable.
- 45:42SPEAKER_00: And I think with those three positions, you should be able to pull off a prep program.
- 45:47SPEAKER_02: I would just add one third important person.
- 45:50SPEAKER_02: I think that our linkage to care coordinators do a fantastic job because they're able to have a lot more longer conversations and more detailed counseling conversations with folks that are considering uh PrEP, which is always a challenge, particularly in a hospital setting where a lot of the healthcare providers are very busy and may not take the time to actually answer all the questions.
- 46:16SPEAKER_02: So I would say the linkage to care coordinators are an important piece for our program.
- 46:22SPEAKER_03: Great.
- 46:22SPEAKER_03: Thank you so much.
- 46:23SPEAKER_03: And so this seems like there's some variation in terms of you know whether oral prep or injection prep is available, what the resources are, but um it the unifying, I think, point is that successful prep delivery almost always depends on clear roles and referral pathways and communication, not necessarily on having a perfect or complete team.
- 46:43SPEAKER_03: So we also want to emphasize that even when only one provider is available, prep can still be delivered effectively with simple tools like handouts or counseling scripts, um, mobile or virtual follow-ups.
- 46:56SPEAKER_03: And support doesn't always have to be specialized.
- 46:58SPEAKER_03: The goal is really about continuity, trust, and actionable steps.
- 47:05SPEAKER_03: So to close, we want to leave you with three uh practical goals you can take back to your healthcare setting.
- 47:12SPEAKER_03: The first is to normalize screening for all patients by using a status neutral approach to HIV screening.
- 47:19SPEAKER_03: Second, use results to connect people to prevention or treatment based on what's available in your setting.
- 47:26SPEAKER_03: And third, make communication and team collaboration the backbone of that work.
- 47:31SPEAKER_03: No matter your role or region, adopting a status neutral approach helps to normalize testing, reduce stigma, and ensures that every patient has a clear next step.
- 47:42SPEAKER_03: Thank you to our wonderful faculty for sharing your perspectives, and thank you to our audience for joining us.
- 47:48SPEAKER_03: This activity is part of a broader HIV prevention education series.
- 47:53SPEAKER_03: Additional programs will explore topics including long acting injectable prep, patient engagement and adherence strategies, and expanding access to newer prevention options.
- 48:04SPEAKER_03: We encourage you to explore these programs and to continue building on today's discussion.